» Articles » PMID: 28240749

Regression in Primary Cutaneous Melanoma: Etiopathogenesis and Clinical Significance

Overview
Journal Lab Invest
Specialty Pathology
Date 2017 Feb 28
PMID 28240749
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Though not required currently for staging, regression is a histopathologic parameter typically reported upon diagnosis of an invasive primary cutaneous melanoma. The studies examining the prognostic significance of regression in patient outcome have yielded controversial findings; likely because the definition and assessment of regression have not been consistent, in addition to subjectivity of pathologists' interpretation. Regression is histologically characterized by variable decrease in the number of melanoma cells accompanied by the presence of a host response consisting of dermal fibrosis, inflammatory infiltrate, melanophages, ectatic blood vessels, epidermal attenuation, and/or apoptosis of keratinocytes or melanocytes; the relative extent of these features depends on the stage of the regression. However, the magnitudes to which these individual changes must be present to meet the threshold of histologic regression have not been well defined or agreed upon, and thus, the definition and classification of histologic regression in melanoma varies considerably among institutions and even among individual pathologists. In order to determine the clinical significance of histologic analysis of regression, there is a compelling need for a universal scheme to objectively define and assess histologic regression in primary cutaneous melanoma, so that the biologic and prognostic significance of this process may be completely understood.Laboratory Investigation advance online publication, 27 February 2017; doi:10.1038/labinvest.2017.8.

Citing Articles

Defining the high-risk category of patients with cutaneous melanoma: a practical tool based on prognostic modeling.

Dudin O, Mintser O, Gurianov V, Kobyliak N, Kozakov D, Livshun S Front Mol Biosci. 2025; 12:1543148.

PMID: 39990871 PMC: 11842245. DOI: 10.3389/fmolb.2025.1543148.


Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features.

Paolino G, Pampena R, Di Ciaccio S, Carugno A, Cantisani C, Di Nicola M Medicina (Kaunas). 2024; 60(8).

PMID: 39202520 PMC: 11356094. DOI: 10.3390/medicina60081239.


Contribution of Keratinocytes in Skin Cancer Initiation and Progression.

Dainese-Marque O, Garcia V, Andrieu-Abadie N, Riond J Int J Mol Sci. 2024; 25(16).

PMID: 39201498 PMC: 11354502. DOI: 10.3390/ijms25168813.


Association of miR-146a-5p and miR-21-5p with Prognostic Features in Melanomas.

Naddeo M, Broseghini E, Venturi F, Vaccari S, Corti B, Lambertini M Cancers (Basel). 2024; 16(9).

PMID: 38730639 PMC: 11083009. DOI: 10.3390/cancers16091688.


Strategies for improving the performance of prediction models for response to immune checkpoint blockade therapy in cancer.

Zeng T, Zhang J, Stromberg A, Chen J, Wang C BMC Res Notes. 2024; 17(1):102.

PMID: 38594730 PMC: 11005243. DOI: 10.1186/s13104-024-06760-5.


References
1.
Cooper P, Wanebo H, Hagar R . Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol. 1985; 121(9):1127-31. View

2.
Gromet M, Epstein W, Blois M . The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978; 42(5):2282-92. DOI: 10.1002/1097-0142(197811)42:5<2282::aid-cncr2820420528>3.0.co;2-v. View

3.
Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

4.
Traversari C, van der Bruggen P, Luescher I, Lurquin C, Chomez P, Van Pel A . A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992; 176(5):1453-7. PMC: 2119413. DOI: 10.1084/jem.176.5.1453. View

5.
Paladugu R, YONEMOTO R . Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983; 118(1):41-4. DOI: 10.1001/archsurg.1983.01390010031008. View